Researchers have discovered that in mice with cancers in the liver, immunotherapy and radiotherapy prevented T-cell death.
List view / Grid view
Non-small cell lung cancer (NSCLC)
A new study has suggested that the enzyme GFPT2 could be a useful target for non-small cell lung cancer (NSCLC).
According to the study, the transcription factor IRF4 drives T cell differentiation and immunosuppression in multiple human cancers.
Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
A study has discovered the mechanism behind NSCLC resistance to chemotherapy, which could improve treatment strategies for the condition.